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Abstract In the present study, we demonstrate that the Ca 2+- 
inhibitable adenylyl cyclase (AC) activity in the striatum exhibits 
a daily oscillation with a peak occurring around 10:00 h. A 
circadian fluctuation of the AC activity evoked by an A2a 
adenosine-selective agonist was also observed, lntrastriatal 
injection of an A2a-selective adenosine agonist or antagonist 
during the interval in which the Ca2+-inhibitable AC activity was 
at its peak resulted in a more significant alteration of locomotor 
activity than those observed at a later interval. The marked 
circadian variation in the Ca2+-inhibitable AC activity in the 
striatum appears to cause a circadian fluctuation in the action of 
at least one neuromodulator. 
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1. Introduction 
Genes of at least 10 distinct mammalian cyclases (ACs), 
which can be further divided into five subfamilies, have been 
reported [1]. Although these enzymes can all be activated by 
the a subunit of Gs proteins, each is under very distinct reg- 
ulation. For example, some ACs (AC5 and AC6) can be in- 
hibited by Ca 2+, while others (AC1, AC3 and AC8) are acti- 
vated by Ca 2+ in the presence of calmodulin [2]. In addition, a 
recently cloned AC subtype, AC10, was found to be inhibited 
by Ca2÷/calmodulin-activated protein phosphatase, calcineur- 
in [3]. This heterogeneous multigene AC family thus appears 
to play a very critical role in the integration of multiple sig- 
nals, especially those occurring in the nervous system. Never- 
theless, regulation of these ACs under physiological condi- 
tions remain largely uncharacterized. In the present study, 
we have demonstrated a circadian variation in the Ca2+-inhi - 
bitable adenylyl cyclase (AC) activity in the rat striatum. In 
addition, this circadian regulation of the Ca2+-inhibitable AC 
activity subsequently leads to a circadian fluctuation of the 
cAMP signaling evoked by one AC-coupled neuromodulator, 
adenosine, in the striatum. 
2. Materials and methods 
2.1. Materials 
Adenosine, 8-(3-chlorostyryl)caffeine, and CGS21680 were obtained 
from Research Biochemicals Int. (Natick, MA, USA). Forskolin and 
cAMP were obtained from Sigma (MO, USA). 
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2.2. Adenylyl cyclase assay 
Adenylyl cyclase activity was assayed as described previously [4] 
with slight modification. In brief, the striatum tissues were removed, 
and sonicated in ice-chilled lysis buffer (10 mM EDTA, 20 mM Tris, 
250 mM sucrose, 1 mM PMSF amd 40 jaM leupeptin, pH 7.4) using 
an ultrasonic ell disrupter (40% output power) for a total of 45 
seconds. The homogenate was centrifuged at 40000×g for 30 min 
and the membrane fractions and cytosolic fractions collected. Adeny- 
lyl cyclase activity assay was performed at 37°C for 10 min in a 400-jal 
reaction mixture containing 1 mM ATP, 100 mM NaC1, 50 mM 
HEPES, 6 rnM MnCI2, 1 JaM GTP, 0.5 mM 3-isobutyl-l-methyl- 
xanthine (IBMX) and 20 ixg membrane protein. Reactions were 
stopped by 0.6 ml 10% TCA. The cAMP formed was isolated by 
Dowex chromatography (Sigma) and assayed by radioimmunoassay 
as described [4]. No significant difference was found by adding 20 mM 
creatine phosphate (Sigma), and 100 U/ml creatine phosphokinase 
(Sigma) to the cyclase reaction. The enzyme activity was linear up 
to 20 min with protein up to 100 Jag. All samples were assayed in 
triplicate. 
2.3. Animals and Drug administration i striatum 
Male Sprague-Dawley rats (~250 g) were obtained from the In- 
stitute of Biomedical Sciences/Academia S nica. Animals were housed 
three per cage under a 12-h light/dark cycle (light on at 6:30 h). Rats 
were subject o stereotaxic surgery. Twenty-three-gauge stainless teel 
cannulae were implanted bilaterally into the striatum at the following 
coordinates: AP, + 0.4 mm from bregma; ML, + 2.7 mm from mid- 
line; and DV, -5.4 mm below the skull surface). One week following 
surgery, the desired reagent was injected into the striatum through a 
30-gauge injection eedle connected to a 10 lal Hamilton microsyringe 
by 0.5 m polythylene tubing. Drug solutions were introduced into the 
PE tubing and delivered into the striatum through the injection eedle 
manually at a rate of 0.5 ~tl/min. A volume of 1.5 I.tl was injected into 
each striatum for all animals. Two minutes ubsequent to each injec- 
tion, locomotor activity was measured for 10 min as described else- 
where [5]. Briefly, animals were placed in an activity monitor (Coul- 
bourn Instrument, PA, USA) equipped with 16x16 horizontal 
sensors. These sensors were used to localize the animal's floor posi- 
tion. Locomotor activity was measured by total number of beam 
breaks in an XY  plane recorded every 10 ms. 
3. Results and discussion 
To determine whether the CaZ+-inhibitable AC activity in 
the rat striatum exhibited a circadian fluctuation, we removed 
striatum tissues at 4-h intervals across a 24-h period, and 
determined the AC activity. As shown in Fig. 1, the Ca 2+- 
inhibitable AC activity exhibited a daily oscillation with a 
peak occurring around 10:00 h. The adenylyl cyclase activity 
evoked by forskolin (5 I.tM) in the absence or presence of 
calcium (30 I.tM) at 2:00 h is 1397+475 pmole/mg per min 
and 84 + 32 pmole/mg per min respectively (12 determinants 
from 4 animals), suggesting that more than 90% of the for- 
skolin-evoked AC activity in the striatum is Ca2+-inhibitable 
under our experimental conditions. Therefore, the Ca2+-inhi - 
bitable AC must play an important role in the striatum. Our 
results are consistent with the notion that expression of Ca2+/ 
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Fig. 1. Circadian regulation of the Ca2+-inhibitable AC activity. 
Membrane fractions were collected from the striatum, washed twice 
in an EGTA buffer to remove the endogenous calcium and resus- 
pended in a EGTA/calcium buffer to control the free calcium con- 
centration at zero or 30 gM for adenylyl cyclase assay. The Ca 2+- 
inhibitable AC activities in response to forskolin (5 gM) at the indi- 
cated time of day were then determined. Values represent the 
mean+S.E.M, of 12 determinations from 4 animals, and are ex- 
pressed as percentages of the Ca2+-inhibitable AC activity 
(1397+475 pmole/mg per rain) at 2:00 h. The closed bars represent 
the dark phase. 
calmodulin-stimulated AC activity in the striatum is relatively 
low [6]. Such circadian regulation of the Ca2+-inhibitable AC
activity appears to be region-specific. For example, no signifi- 
cant circadian variation in the Ca2+-inhibitable AC activity 
was observed in the hippocampus (data not shown). 
To reduce the possible influence of Gsct on AC activity [7], 
we substituted GDPI3S and MnC12 for GTP and MgCl2 re- 
spectively in our AC assay (Fig. 2). Although GDPI3S/MnC12 
markedly reduced the Ca2+-inhibitable AC activity, both total 
AC activity and the Ca2+-inhibitable AC activity at 10:00 h in 
the striatum remained significantly higher than those at 2:00 h 
(Fig. 2). In addition, no significant change in the Gsa protein 
levels was detected throughout the 24-h period (n = 2, data 
not shown). These results uggest that regulation of the effec- 
tor enzyme itself, but not Gst~ protein, may lead to the circa- 
dian variation of the Ca2+-inhibitable AC activity. 
At present, wo Ca2+-inhibitable ACs (AC5 and AC6) have 
been identified [8]. Both Acs are inhibited by physiologically 
relevant, low micromolar concentrations of Ca 2+, and have 
been reported to exist in the brain [8,9]. Using in situ hybri- 
dization analysis, Mons and Cooper [10] demonstrated that 
AC5 mRNA exhibits a highly selective distribution in the 
striatum, while AC6 mRNA exists ubiquitously at relatively 
very low levels throughout the rat brain. In addition, AC5 
transcripts were found to coexist with Dl-dopamine receptor 
and M 1-muscarinic receptor in medium-sized striatal neurons 
[10], suggesting a potentially significant role of AC5 in inte- 
grating dopaminergic and muscarinic signals. Although the 
transcript levels of AC5 are significantly higher than those 
of AC6 in the striatum, the regional expressions of the func- 
tional AC5 and AC6 proteins are currently unknown due to 
the lack of highly specific sub-type antisera. Therefore it can- 
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not be stated which Ca2+-inhibitable AC is under circidian 
regulation in the striatum. 
Recent studies uggest that each isoform of AC is expressed 
distinctly in specific regions of the brain [11]. The specific 
tissue distribution of these different ACs supports biochemical 
evidence for distinct modes of regulation of cAMP levels [1]. 
Regulation of the AC family has thus aroused a great deal of 
interest in the past few years. Recently, protein phosphoryla- 
tion has been implicated in the modulation of AC activities. 
For example, AC6 has been reported to be inhibited by pro- 
tein kinase A (PKA) in a feedback inhibition manner [12]. In 
PC12 cells, we have previously reported that phosphorylation 
of AC6 may account for its inhibition during desensitization 
of A2a adenosine receptor (A2a-R)-mediated cAMP response 
[13]. Most intriguingly, activity of AC5 was found to be up- 
regulated by PKC-mediated phosphorylation, but inhibited by 
PKA-mediated phosphorylation [14,15]. Since circadian regu- 
lation of protein kinase activities and protein phosphorylation 
have been shown in several different tissues [16,17], phosphor- 
ylation thus has become one of the most plausible molecular 
mechanisms underlying the circadian rhythm of the Ca2+-in - 
hibitable AC activity. 
Rapid changes in receptor function over 24 h in the central 
nervous ystem have been reported for many different neuro- 
transmitters [18]. In addition to circadian fluctuation of recep- 
tor activities, our finding suggests that circadian regulation of 
the Ca2+-inhibitable AC activity may also produce circadian 
fluctuations of receptor-mediated cAMP levels. To test the 
above hypothesis, we have examined the AC activity evoked 
by an AC-coupled A2a-R. As demonstrated in Fig. 3, AC 
activity evoked by an A2a-selective agonist, CGS21680, also 
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Fig. 2. Circadian regulation of the Ca2+-inhibitable AC activity was 
largely independent of a change in Gs~t activity. AC activities were 
measured in the presence of GDPI]S (500 I.tM) and MnC12 (10 mM) 
as described in section 2. Values represent the mean + S.E.M. of at 
least 5 determinations from 2 animals. Statistical significance: 
*P < 0.05 compared to the FK-evoked AC activity at 2:00 h, 
**P < 0.01 compared to the FK-evoked AC activity in the absence 
of Ca 2+ at 10:00 h (two-tailed Student's test). 
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exhibited a circadian fluctuation which peaked around 10:00 
h. Again the Ca2+-inhibitable AC activity constituted at least 
90% of the A2a-R-stimulated AC activity under our experi- 
mental conditions. This observation supports the hypothesis 
that the circadian regulation of the effector enzyme itself may 
produce a daily oscillation of the receptor's ignal. 
To examine whether the circular variation of A2a-R-in- 
duced cAMP response in the striatum has any physological 
significance, an A2a-selective agonist (CGS21680) or an an- 
tagonist [8-(3-chlorostyryl)caffeine] [19 was injected intrastri- 
atally. Since one of the striatal functions is control of move- 
ment, we determined the locomotor activity of these drug- 
treated animals. Interestingly, an inverse phase pattern was 
observed between the activity and the cAMP contents (Fig. 
4). CGS21680 (CGS), which resulted in an elevation of cellu- 
lar cAMP content, significantly reduced locomotor activity in 
rats at the interval (9:30-10:30 h) in which the Ca2+-inhibi - 
table AC activity was at its peak, but not at a later interval 
(16:30-17:30 h) when the Ca2+-inhibitable AC activity was 
relatively low. Injection of the A2a-selective antagonist (CSC) 
markedly enhanced locomotor activity at both time intervals 
tested, suggesting that a portion of the striatal A2a-R was 
active under physiological conditions. Again, the effect of 
CSC is more significant around 10:00 h than that observed 
around 17:00 h. These results suggest hat circadian regula- 
tion of the Ca2+-inhibitable AC activity might contribute to 
the circadian oscillation of the physiological functions of a 
neuromodulator. 
Various lines of evidence suggest a powerful antagonistic 
A2a (adenosine)-D2 (dopamine) interaction in the ventral 
striatal system [20]. Therefore, A2a-selective agonists or an- 
tagonists might be useful in the treatment of movement dis- 
orders caused by a dysfunction of the striatal dopaminergic 
50 
250- 
200 - 
,< 150- 
'~1 100- 
I I I I I I I I I I I I 
2 4 6 8 10 12 14 16 18 20 22 24 
The  t ime o f  day  
Fig. 3. Circadian regulation of the A2a-R-evoked AC activity. 
Membrane fractions from the striatum were obtained as described 
in Fig. 1. The total AC (open squares) and the Ca2+-inhibitable AC
activities (closed circles) in response to CGS21680 (100 p.M) at the 
indicated time of day were then determined. Values represent the 
mean+S.E.M, of 12 determinations from 4 animals, and are ex- 
pressed as percentages of the total AC activity (194+ 60 pmole/mg 
per min) and the Ca2+-inhibitable AC activity (171 +46 pmole/mg 
per min) at 2:00 h. 
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Fig. 4. Effect of an adenosine agonist (CGS21680) and an antago- 
nist [8-(3-chlorostyryl)caffeine] on locomotor activity. Animals were 
intrastriatally injected with 1.5 gl of the indicated reagent [SAL, 2% 
DMSO in saline; CGS, CGS21680, 1 gg/gl; CSC, 8-(3-chlorostyryl)- 
caffeine, 0.02 gg/gl] bilaterally in the morning (9:30-10:30 h) or 
afternoon (16:30-17.30 h). Two minutes after the injection, locomo- 
tor activities were measured for 10 min as described in section 2. 
Statistical significance: differences between drug-treated animals and 
vehicle-injected control animals, *P < 0.05 and **P < 0.01, respec- 
tively; ANOVA test. 
neurotransmission, such as Parkinson's disease and Hunting- 
ton's disease [21]. Our observations suggest that adenosine 
agonists and antagonists appear to have a better manipulation 
of locomotor activity when the Ca 2+-inhibitable AC activity is 
at its peak, and therefore may lead to a greater therapeutic 
application of adenosine in the treatment of movement dis- 
orders. 
Anholt [22] has proposed an intriguing and attractive hy- 
pothesis that ACs might serve as 'molecular coincidence de- 
tectors' in the nervous system to integrate and to screen for 
'meaningful signals' from noise. In the present study, we re- 
port that the Ca2+-inhibitable AC activity in the striatum 
exhibited a circadian fluctuation with one clear peak occurring 
at 10:00 h. Such significant variation in the Ca2+-inhibitable 
AC activity throughout the day led to a circadian fluctuation 
in the action of at least one neuromodulator, and may effec- 
tively contribute to the well-known circadian rhythms of sus- 
ceptibility to many central nervous system drugs. 
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